Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Current Liabilities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Total Current Liabilities for 4 consecutive years, with $22.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 11.13% to $22.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.0 million, a 11.13% increase, with the full-year FY2024 number at $129.8 million, up 627.23% from a year prior.
  • Total Current Liabilities was $22.0 million for Q3 2025 at Century Therapeutics, up from $14.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $129.8 million in Q4 2024 to a low of $14.5 million in Q1 2025.
  • A 4-year average of $28.1 million and a median of $20.4 million in 2023 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 627.23% in 2024; the steepest drop was 41.97% in 2024.
  • Century Therapeutics' Total Current Liabilities stood at $29.8 million in 2022, then tumbled by 40.15% to $17.8 million in 2023, then skyrocketed by 627.23% to $129.8 million in 2024, then plummeted by 83.03% to $22.0 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Total Current Liabilities are $22.0 million (Q3 2025), $14.9 million (Q2 2025), and $14.5 million (Q1 2025).